News

People with ANCA-associated vasculitis who have high levels of a protein called aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) in their blood serum might be at higher risk of developing a severe form of the disease, a study has found. The study, “Serum Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1…

Patients with ANCA-associated vasculitis (AAV) with low levels of complement proteins develop greater kidney damage, according to new research. The study, “Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study,” appeared in the journal Clinical Rheumatology. The complement system — a…

In the rare event that ANCA-associated vasculitis affects a large blood vessel like the aorta, treatment with Rituxan (rituximab) appears to improve symptoms and reduce inflammation, a case report shows. The study, “Aortitis caused by antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a case-based review,” was published in…

Major infections are the main cause of poor long-term outcomes and death in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, a Spanish study found. The study, “Prevalence and Risk Factors for Major Infections In Patients with Anca-associated Vasculitis. Influence on The Disease Outcome,” was published in…

A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…